• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lantheus Holdings Inc. (Amendment)

    2/13/24 5:08:02 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email
    SC 13G/A 1 tv01317-lantheusholdingsinc.htm SCHEDULE 13G/A lantheusholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Lantheus Holdings Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  516544103

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  516544103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    124,793

    7.  SOLE DISPOSITIVE POWER

    6,775,448

    8.  SHARED DISPOSITIVE POWER

    197,693

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,973,141

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.18%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Lantheus Holdings Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    201 Burlington Road, South Building
    Bedford, MA 01730

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    516544103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $LNTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    2/26/2026Mkt Perform → Outperform
    William Blair
    12/12/2025$80.00Hold → Buy
    Truist
    10/8/2025$77.00Buy → Neutral
    Goldman
    8/12/2025$63.00Buy → Hold
    Truist
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $LNTH
    SEC Filings

    View All

    SEC Form SD filed by Lantheus Holdings Inc.

    SD - Lantheus Holdings, Inc. (0001521036) (Filer)

    5/29/26 4:30:28 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

    SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    5/15/26 12:38:41 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Lantheus Holdings Inc.

    10-Q - Lantheus Holdings, Inc. (0001521036) (Filer)

    5/7/26 7:44:51 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ber Gerard covered exercise/tax liability with 381 shares, decreasing direct ownership by 1% to 27,118 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    6/3/26 4:44:22 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Executive Chair and CEO Heino Mary Anne covered exercise/tax liability with 1,227 shares, decreasing direct ownership by 0.38% to 321,897 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    6/3/26 4:43:54 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Mchugh Julie was granted 4,137 shares, increasing direct ownership by 16% to 30,099 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    5/18/26 4:37:27 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

    3/8/24 11:24:53 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings upgraded by William Blair

    William Blair upgraded Lantheus Holdings from Mkt Perform to Outperform

    2/26/26 12:20:43 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings upgraded by Truist with a new price target

    Truist upgraded Lantheus Holdings from Hold to Buy and set a new price target of $80.00

    12/12/25 8:36:54 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings downgraded by Goldman with a new price target

    Goldman downgraded Lantheus Holdings from Buy to Neutral and set a new price target of $77.00

    10/8/25 8:24:33 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9. To access the live webcast of the presentations, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcasts will be available on the Company's website for at least 30 days followi

    6/3/26 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year

    BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI's Image of the Year at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles, California. The recognition was presented in connection with investigator-initiated trial results evaluating LNTH-2513 PET/CT for the detection of acute lower-extremity deep vein thrombosis (DVT) in symptomatic patients. "These resu

    6/2/26 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

    BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3. To access the live webcast of the presentations, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcasts will be available on the Company's website for at least 30 days following

    5/27/26 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Financials

    Live finance-specific insights

    View All

    Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

    Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025Adjusted fully diluted earnings per share of $1.46, compared to $1.53 in the first quarter of 2025FDA approves PYLARIFY TruVuTM (piflufolastat F18); phased geographic launch planned to begin in the fourth quarter of 2026FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003); expected to be the first radioequivalent for the treatment of gastroenteropancreatic neuroendocrine tumorsReaffirmed previously issued corporate guidance for full year 2026 revenue and adjusted fully diluted earnings per share BEDF

    5/7/26 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 7, 2026, to discuss its financial results and provide a business update for the first quarter of 2026. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 d

    4/23/26 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growthCompany provides full year 2026 rev

    2/26/26 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

    BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

    7/22/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

    BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

    1/30/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

    SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 3:29:28 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    2/14/24 1:18:20 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care